AMAR REMEDIES | LINC PEN & PLASTICS | AMAR REMEDIES/ LINC PEN & PLASTICS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -0.5 | 14.0 | - | View Chart |
P/BV | x | 0.1 | 2.5 | 2.4% | View Chart |
Dividend Yield | % | 0.0 | 1.8 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AMAR REMEDIES Jun-12 |
LINC PEN & PLASTICS Mar-16 |
AMAR REMEDIES/ LINC PEN & PLASTICS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 164 | 243 | 67.6% | |
Low | Rs | 86 | 136 | 63.2% | |
Sales per share (Unadj.) | Rs | 261.6 | 232.7 | 112.4% | |
Earnings per share (Unadj.) | Rs | 17.4 | 12.4 | 140.4% | |
Cash flow per share (Unadj.) | Rs | 22.3 | 16.4 | 135.7% | |
Dividends per share (Unadj.) | Rs | 0 | 3.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 1.6 | 0.0% | |
Book value per share (Unadj.) | Rs | 100.7 | 68.4 | 147.3% | |
Shares outstanding (eoy) | m | 26.16 | 14.79 | 176.9% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 0.5 | 0.8 | 58.7% | |
Avg P/E ratio | x | 7.2 | 15.3 | 47.0% | |
P/CF ratio (eoy) | x | 5.6 | 11.5 | 48.6% | |
Price / Book Value ratio | x | 1.2 | 2.8 | 44.8% | |
Dividend payout | % | 0 | 24.2 | 0.0% | |
Avg Mkt Cap | Rs m | 3,270 | 2,800 | 116.8% | |
No. of employees | `000 | NA | 0.7 | 0.0% | |
Total wages/salary | Rs m | 163 | 186 | 87.8% | |
Avg. sales/employee | Rs Th | NM | 5,167.3 | - | |
Avg. wages/employee | Rs Th | NM | 278.8 | - | |
Avg. net profit/employee | Rs Th | NM | 275.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,844 | 3,441 | 198.9% | |
Other income | Rs m | 21 | 7 | 284.6% | |
Total revenues | Rs m | 6,865 | 3,449 | 199.1% | |
Gross profit | Rs m | 1,131 | 314 | 360.3% | |
Depreciation | Rs m | 128 | 60 | 214.6% | |
Interest | Rs m | 398 | 15 | 2,601.3% | |
Profit before tax | Rs m | 626 | 246 | 254.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -50 | 0 | - | |
Tax | Rs m | 121 | 63 | 191.5% | |
Profit after tax | Rs m | 455 | 183 | 248.4% | |
Gross profit margin | % | 16.5 | 9.1 | 181.2% | |
Effective tax rate | % | 19.3 | 25.6 | 75.4% | |
Net profit margin | % | 6.6 | 5.3 | 124.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 4,904 | 1,334 | 367.7% | |
Current liabilities | Rs m | 3,581 | 802 | 446.7% | |
Net working cap to sales | % | 19.3 | 15.5 | 125.0% | |
Current ratio | x | 1.4 | 1.7 | 82.3% | |
Inventory Days | Days | 124 | 82 | 151.6% | |
Debtors Days | Days | 100 | 51 | 197.9% | |
Net fixed assets | Rs m | 1,689 | 437 | 386.2% | |
Share capital | Rs m | 262 | 148 | 177.2% | |
"Free" reserves | Rs m | 2,358 | 863 | 273.1% | |
Net worth | Rs m | 2,635 | 1,011 | 260.6% | |
Long term debt | Rs m | 507 | 0 | - | |
Total assets | Rs m | 6,862 | 1,855 | 370.0% | |
Interest coverage | x | 2.6 | 17.1 | 15.0% | |
Debt to equity ratio | x | 0.2 | 0 | - | |
Sales to assets ratio | x | 1.0 | 1.9 | 53.8% | |
Return on assets | % | 12.4 | 10.7 | 116.2% | |
Return on equity | % | 17.3 | 18.1 | 95.3% | |
Return on capital | % | 31.0 | 25.9 | 119.8% | |
Exports to sales | % | 4.0 | 27.9 | 14.3% | |
Imports to sales | % | 0 | 16.0 | 0.0% | |
Exports (fob) | Rs m | 273 | 959 | 28.5% | |
Imports (cif) | Rs m | NA | 552 | 0.0% | |
Fx inflow | Rs m | 273 | 960 | 28.4% | |
Fx outflow | Rs m | 2 | 577 | 0.3% | |
Net fx | Rs m | 271 | 383 | 70.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -313 | 97 | -322.6% | |
From Investments | Rs m | -489 | -185 | 264.5% | |
From Financial Activity | Rs m | 769 | 74 | 1,037.5% | |
Net Cashflow | Rs m | -33 | -14 | 236.5% |
Indian Promoters | % | 25.5 | 60.4 | 42.2% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 9.2 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 65.3 | 39.6 | 164.9% | |
Shareholders | 13,061 | 6,688 | 195.3% | ||
Pledged promoter(s) holding | % | 99.7 | 0.0 | - |
Compare AMAR REMEDIES With: COLGATE HUL BAJAJ CONSUMER CARE GODREJ INDUSTRIES JYOTHY LABS
Compare AMAR REMEDIES With: P&G (US) UNILEVER PLC. (UK) HYPERMARCAS (Brazil)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More